GEP20125516B - Therapeutic uses of inhibitors of rtp801 - Google Patents

Therapeutic uses of inhibitors of rtp801

Info

Publication number
GEP20125516B
GEP20125516B GEAP2005009869A GEP20125516B GE P20125516 B GEP20125516 B GE P20125516B GE AP2005009869 A GEAP2005009869 A GE AP2005009869A GE P20125516 B GEP20125516 B GE P20125516B
Authority
GE
Georgia
Prior art keywords
rtp801
inhibitors
therapeutic uses
rnk
respiratory
Prior art date
Application number
Inventor
Elena Feinstein
Klaus Giese
Joerg Kaufmann
Original Assignee
Quark Biotech Inc
Silence Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc, Silence Therapeutics filed Critical Quark Biotech Inc
Publication of GEP20125516B publication Critical patent/GEP20125516B/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The novel compound of interference siRNA RNK molecule, pharmaceutical composition containing it and its use for treating eye diseases or respiratory or microvascular disorders based upon inhibition of the RTP801 gene and/or protein.
GEAP2005009869 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801 GEP20125516B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP04019405 2004-08-16
US60198304P 2004-08-17 2004-08-17
US60466804P 2004-08-25 2004-08-25
US60978604P 2004-09-14 2004-09-14
US63865904P 2004-12-22 2004-12-22
US66423605P 2005-03-22 2005-03-22
US68894305P 2005-06-08 2005-06-08

Publications (1)

Publication Number Publication Date
GEP20125516B true GEP20125516B (en) 2012-05-25

Family

ID=39085993

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP2005009869 GEP20125516B (en) 2004-08-16 2005-08-16 Therapeutic uses of inhibitors of rtp801

Country Status (6)

Country Link
CN (1) CN102847154A (en)
DK (1) DK1791568T3 (en)
ES (2) ES2691196T3 (en)
GE (1) GEP20125516B (en)
UA (1) UA92465C2 (en)
ZA (1) ZA200701364B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1009753B1 (en) * 1997-08-21 2005-04-20 Quark Biotech, Inc. Hypoxia-regulated genes
EP2233926A3 (en) * 2003-04-01 2011-01-12 The Johns Hopkins University Breast Endothelial Cell Expression Patterns
JP2005095173A (en) * 2003-09-04 2005-04-14 Masaomi Nangaku Method for detection of hypoxia response
AU2004294950A1 (en) * 2003-11-26 2005-06-16 Entelos, Inc. Treatment of rheumatoid arthritis with Hypoxia-Inducible Factor 1alpha antagonists
US20050215503A1 (en) * 2003-12-03 2005-09-29 Mcevoy Leslie M HIF oligonucleotide decoy molecules

Also Published As

Publication number Publication date
UA92465C2 (en) 2010-11-10
DK1791568T3 (en) 2012-12-10
ES2390085T3 (en) 2012-11-06
CN102847154A (en) 2013-01-02
ES2691196T3 (en) 2018-11-26
ZA200701364B (en) 2008-04-30

Similar Documents

Publication Publication Date Title
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
ATE442142T1 (en) FREDERICAMYCIN DERIVATIVES AS DRUGS FOR TUMOR TREATMENT
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
TW200508214A (en) Novel compounds
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
DE50310516D1 (en) Fredericamycin DERIVATIVES
IL181987A0 (en) Diaminotriazole derivatives and pharmaceutical compositions containing the same
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
MY162157A (en) Substituted indole mcl-1 inhibitors
WO2003080582A3 (en) Fredericamycin derivatives
WO2005046603A3 (en) Pyridine compounds
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
SG155921A1 (en) Bicyclic amides as kinase inhibitors
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
TW200738659A (en) Novel compounds
EA200800011A1 (en) THYENOPYRIMIDINE AND THYENOPYRIDINE KINASE MODULATORS
TW200740808A (en) Inhibiteurs de proteines kinases
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
JO2724B1 (en) 3-substituted-5- and 6-Aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity